wiki pageCreated: 2026-04-02T07:19:24By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-genes-sacs
📖 Wiki Page
gene930 wordssynced 2026-04-02
SACS Gene
Introduction
The SACS gene (Sacsin Molecular Chaperone) encodes a very large multidomain protein involved in protein quality control and mitochondrial dynamics. Mutations cause autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder with cerebellar ataxia and spasticity.
The SACS gene is located on chromosome 13q12.12 and encodes sacsin, one of the largest proteins in the human genome at approximately 4,579 amino acids (~520 kDa)<sup>[1]</sup>. Sacsin functions as a molecular chaperone involved in protein folding, mitochondrial quality control, and cytoskeletal dynamics in [neurons](/entities/neurons)<sup>[2]</sup>. Biallelic loss-of-function mutations cause ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay), originally described in the French-Canadian population of Quebec but now recognized worldwide<sup>[3]</sup>. [@anderson2010]
The SACS gene (Sacsin Molecular Chaperone) encodes a very large multidomain protein involved in protein quality control and mitochondrial dynamics. Mutations cause autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder with cerebellar ataxia and spasticity.
Overview
Mermaid diagram (expand to render)
The SACS gene is located on chromosome 13q12.12 and encodes sacsin, one of the largest proteins in the human genome at approximately 4,579 amino acids (~520 kDa)<sup>[1]</sup>. Sacsin functions as a molecular chaperone involved in protein folding, mitochondrial quality control, and cytoskeletal dynamics in [neurons](/entities/neurons)<sup>[2]</sup>. Biallelic loss-of-function mutations cause ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay), originally described in the French-Canadian population of Quebec but now recognized worldwide<sup>[3]</sup>. [@anderson2010]
Peripheral nerve demyelination with onion bulb formation
Connections to Broader Neurodegeneration
ARSACS pathobiology converges with mechanisms in other neurodegenerative diseases<sup>[4]</sup>:
Mitochondrial dysfunction: Shared with [Parkinson's disease](/diseases/parkinsons-disease) ([PINK1](/genes/pink1)/[PRKN](/genes/prkn) pathway) and Friedreich ataxia
Protein misfolding: Chaperone deficiency parallels proteostasis failure in [Alzheimer's disease](/diseases/alzheimers-disease) and [Huntington's disease](/diseases/huntington-disease)
[Autophagy](/entities/autophagy) impairment: Defective mitophagy connects to [ALS](/diseases/amyotrophic-lateral-sclerosis) and PD mechanisms
Purkinje cell vulnerability: Shared target with spinocerebellar ataxias ([ATXN1](/genes/atxn1), [ATXN3](/genes/atxn3))
Common Variants
| Variant | Effect | Population | Phenotype | |---------|--------|------------|-----------| | c.8844delT | Frameshift (p.Ile2949fs) | French-Canadian founder | Classic ARSACS (>90% of Quebec cases) | | c.7504C>T (R2502X) | Nonsense | Pan-ethnic | Severe early-onset ARSACS | | c.5254C>T (R1752X) | Nonsense | Various | Classic ARSACS | | c.2094-2A>G | Splice site | Italian | ARSACS | | c.12220G>C (D4074H) | Missense | Japanese | Milder late-onset ataxia | | Various missense | Partial function | Pan-ethnic | Later onset, slower progression |
Expression
SACS is broadly expressed with highest levels in the nervous system<sup>[1]</sup>:
Cerebellum: Very high expression in [Purkinje cells](/cell-types/purkinje-cells) and deep cerebellar nuclei
Cerebral [cortex](/brain-regions/cortex): Moderate expression in pyramidal neurons
Brainstem: Motor nuclei and pontine nuclei
Spinal cord: Motor neurons (corticospinal tract)
Skeletal muscle: Moderate expression
Skin fibroblasts: Low but detectable (used for diagnosis)
Expression is highest during neuronal differentiation and maturation, consistent with a developmental role<sup>[2]</sup>.
Therapeutic Implications
Gene therapy: AAV-mediated delivery challenging due to extreme cDNA size (~13.7 kb exceeds AAV capacity); dual-vector or truncated approaches under investigation
Pharmacological chaperones: Small molecules that compensate for sacsin loss by enhancing Hsp70/Hsp90 activity
Mitochondrial modulators: Compounds targeting [DRP1](/proteins/drp1-protein) or mitochondrial biogenesis (e.g., bezafibrate)
Antisense approaches: Exon-skipping strategies for specific truncating variants
See Also
[Cerebellum](/brain-regions/cerebellum)
[Purkinje Cells](/cell-types/purkinje-cells)
[Mitochondrial Dynamics in Neurodegeneration](/mechanisms/mitochondrial-dynamics-neurodegeneration)
[Engert JC et al., ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF (2000) (2000)](https://doi.org/10.1038/72167)
[Anderson JF et al., The sacsin repeating region (SRR): a novel Hsp90-related supra-domain associated with neurodegeneration (2010) (2010)](https://doi.org/10.1016/j.jmb.2010.08.009)
[Synofzik M et al., Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum (2013) (2013)](https://doi.org/10.1186/1750-1172-8-41)
[Bradshaw TY et al., A reduction in Drp1-mediated fission compromises mitochondrial health in autosomal recessive spastic ataxia of Charlevoix Saguenay (2016) (2016)](https://doi.org/10.1093/hmg/ddw330)
[Duncan EJ et al., Altered organization of the intermediate filament cytoskeleton and relocalization of proteostasis modulators in cells lacking the ataxia protein sacsin (2017) (2017)](https://doi.org/10.1093/hmg/ddw408)
[Bouchard JP et al., Autosomal recessive spastic ataxia of Charlevoix-Saguenay (1998) (1998)](https://doi.org/10.1016/S0960-8966(97)